Ascites is the buildup of fluid in the abdominal cavity, which often develops as a complication of liver disease. However, ...

Catumaxomab Received a Positive Opinion From the EMA's Committee for Medicinal Products for Human Use (CHMP) at Its October 2024 Meeting and If ...

Bedrest has traditionally been recommended for patients with ascites on the basis that upright posture increases aldosterone levels, which is associated with sodium retention. [11] Although ...

Lindis Biotech has licensed Korjuny (catumaxomab) to Pharmanovia for malignant ascites, offering a targeted immune therapy ...

Ascites is the most common complication of cirrhosis and a major cause of morbidity and hospitalization. Treatment of ascites is initially based on diuretics, but randomized studies assessing the ...

Ascites can develop in patients with cirrhosis as a result of disturbed fluid and electrolyte balance. Not all patients with ascites respond to spironolactone, which is the standard treatment for ...

The agreement gives Pharmanovia the exclusive rights to bring to market, catumaxomab, a first-in-class, trifunctional bi-specific monoclonal antibody, indicated for the intraperitoneal treatment of ...

If approved, Korjuny would become the only drug approved for the specific and cancer-directed treatment of malignant ascites, an abnormal accumulation of fluid in the peritoneal cavity that commonly ...

Catumaxomab received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) at its October 2024 meeting and if approved catumaxomab will be the only approved drug for ...

Total paracentesis has also been shown to be as safe as repeated partial paracentesis and to shorten the period of hospitalization -- and may even be performed on an outpatient basis. [34] However ...